Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.

Cancer chemotherapy and pharmacology - 1 Apr 2005

Wallén Mika, Tomás Eija, Visakorpi Tapio, Holli Kaija, Mäenpää Johanna

Abstract excerpt

PURPOSE: Long-term use of tamoxifen is associated with a two- to threefold increased risk of endometrial cancer in postmenopausal women. Toremifene is another triphenylethylene antiestrogen, which is as effective as tamoxifen in postmenopausal breast cancer. Thus far, its use has not been associated with an increased risk of endometrial cancer. K-ras codon 12 mutations seem to be important in endometrial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrium

Share to Genes, ras

Share to Mutation

Share to Postmenopause

Share to Tamoxifen

Source

Identifiers

PMID: 15592834
DOI: 10.1007/s00280-004-0923-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene.PMID 15592834Read ↗

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.Semantic proximity Read ↗

K-ras mutation in tamoxifen-related endometrial polyps.Semantic proximity Read ↗

Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.Semantic proximity Read ↗

Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.Semantic proximity Read ↗

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.Semantic proximity Read ↗

Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium.Semantic proximity Read ↗

Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations.Semantic proximity Read ↗

Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis.Semantic proximity Read ↗

Mutations of the Ki-ras oncogene in carcinoma of the endometrium.Semantic proximity Read ↗

Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations.Semantic proximity Read ↗

K-ras activation in neoplasms of the human female reproductive tract.Semantic proximity Read ↗

K-ras activation in premalignant and malignant epithelial lesions of the human uterus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.